

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

**VOLUNTARY ANNOUNCEMENT
ESTABLISHMENT OF
BIOLOGICS MANUFACTURING CENTER**

This is a voluntary announcement made by Genscript Biotech Corporation (the “**Company**” and together with its subsidiaries collectively referred to as the “**Group**”). The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company proposes to invest US\$75 million (approximately HK\$590 million) to establish a biologics clinical and commercial manufacturing center (the “**Manufacturing Center**”) in the city of Zhenjiang, the People’s Republic of China (the “**PRC**”).

According to the development plan of the Company, the Manufacturing Center will be used as a facility for the production of clinical samples and commercialized biologics, and will include functional areas for the production, filling, quality control and cold chain logistics for biologics, warehouse facilities for raw and auxiliary materials, energy center and other purposes. The production facilities will be designed and constructed in compliance with the good manufacturing practice (GMP) requirements of the United States, the European Union and the PRC, and will employ the world’s leading single-use bioreactor technology. The total production capacity of the Manufacturing Center is estimated to reach 5,700 liters. Upon commencement of operation of the Manufacturing Center, the Company will be able to meet both domestic and foreign customers’ needs for Phases I to III clinical sample production and commercial production.

The construction of the Manufacturing Center is a major milestone of the Company in the field of biologics contract development and manufacturing operations (CDMO). It is expected that the Company will establish an integrated platform for biologics discovery, development, clinical production and commercial production in the next

two years, which will provide a more convenient one-stop service for Chinese and global partners, with the aim of meeting the increasing demand for the development and production of biologics, and accelerating the conversion of biologics from targets to products.

The Board believes that the establishment of the Manufacturing Center is in the interest of the Company and its shareholders as a whole. The Company will make further announcements in relation to the Manufacturing Center as and when appropriate and/or required under the Listing Rules.

The shareholders and potential investors of the Company are advised to act prudently while trading in the shares of the Company.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 5 July 2018

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*